Insilico Medicine released a preprint describing LEGION (Latent Enumeration, Generation, Integration, Optimization and Navigation), an AI workflow designed to enumerate and defend vast regions of chemical space around a target—applied to NLRP3 in the case study. LEGION aims to accelerate lead generation while generating portfolios that make it harder for competitors to patent near‑identical compounds. Insilico said it used LEGION to support ISM8969, an oral NLRP3 inhibitor nearing IND submission. The approach illustrates how generative chemistry can both expand discovery reach and create strategic IP coverage. For drug developers, the workflow represents a combined scientific and commercial play: speed up hit finding, broaden candidate diversity, and erect patent fences to protect long‑term value in high‑priority targets such as NLRP3.